A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years

Yuriko Maruyama, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Makoto Naganuma, Nagamu Inoue, Haruhiko Ogata, Yasushi Iwao, Takanori Kanai, Toshifumi Hibi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Behçet's disease is a chronic relapsing disease with multiple organ system involvement, including the gastrointestinal tract, which is known as intestinal Behçet's disease. Intestinal Behçet's disease is often resistant to empirical treatments such as 5-aminosalicylic acid, immunomodulators and steroids and often causes a perforation, requiring surgical resection. Therefore, intestinal lesions are considered to be a poor prognostic factor in Behçet's disease. Recently, several reports have demonstrated the efficacy of anti-TNFα monoclonal antibodies, such as infliximab, against intestinal Behçet's disease, however, it remains unknown whether anti- TNFα therapy can improve the prognosis of patients with intestinal Behçet's disease. We herein report the case of an adult female patient with intestinal Behçet's disease who responded well to the induction therapy with infliximab, and has been maintained in remission by scheduled administration of infliximab. Her C- reactive protein level has been sustained at a negative level, and endoscopic findings revealed complete mucosal healing. Therefore, infliximab may have the potential to induce "sustained deep remission" in patients with intestinal Behçet's disease.

Original languageEnglish
Pages (from-to)2125-2129
Number of pages5
JournalInternal Medicine
Volume51
Issue number16
DOIs
Publication statusPublished - 2012 Aug 23

Keywords

  • Infliximab
  • Intestinal Behçet's disease
  • Mucosal healing
  • Sustained deep remission

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years'. Together they form a unique fingerprint.

  • Cite this